|
Indications for VKA treatment |
Estimated risk of thromboembolism |
||
|
Low |
Moderate |
High |
|
|
Mechanical heart valve |
Mechanical bileaflet aortic valve with no additional stroke risk factors |
Mechanical bileaflet aortic valve and one of the following risk factors: AF, history of stroke/TIA, hypertension, diabetes mellitus, congestive heart failure, age >75 years |
– Mechanical mitral valve; old-type mechanical aortic valve (caged-ball, tilting-disc) – History of stroke or TIA in prior 6 months |
|
Atrial fibrillation |
CHADS2 score 0-2 and no history of stroke or TIA |
CHADS2 score 3-4 |
– CHADS2 score 5-6 – History of stroke or TIA in prior 3 months – Rheumatic heart disease |
|
VTE |
History of 1 VTE event >12 months ago, currently no other risk factors for VTE |
– History of VTE in prior 3-12 months or recurrent VTE – Milder forms of thrombophilia (eg, heterozygotes for prothrombin G20210A gene or factor V Leiden) |
– History of VTE in prior 3 months – Severe thrombophilia (eg, antithrombin, protein C or protein S deficiency, APS, several coexisting conditions) – Cancer (treatment in prior 6 months or palliative therapy) |
|
CHADS2 score: see table 3.4-2. |
|||
|
AF, atrial fibrillation; APS, antiphospholipid syndrome; TIA, transient ischemic attack; VKA, vitamin K antagonist; VTE, venous thromboembolism. |
|||